Zdinak, Paul M.
Trivedi, Nishtha
Grebinoski, Stephanie
Torrey, Jessica
Martinez, Eduardo Zarate http://orcid.org/0000-0001-6411-3563
Martinez, Salome
Hicks, Louise
Ranjan, Rashi http://orcid.org/0000-0002-8303-7815
Makani, Venkata Krishna Kanth
Roland, Mary Melissa
Kublo, Lyubov
Arshad, Sanya
Anderson, Mark S. http://orcid.org/0000-0002-3093-4758
Vignali, Dario A. A. http://orcid.org/0000-0002-2771-5992
Joglekar, Alok V. http://orcid.org/0000-0001-7554-7447
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1R03DK127447-01)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP2 OD033187-01)
dkNET New Investigator Award In Bioinformatics Pittsburgh Autoimmunity Center for Excellence in Rheumatology Innovative Discovery Award
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (5T32AI089443-14)
Article History
Received: 20 November 2022
Accepted: 22 March 2024
First Online: 24 April 2024
Competing interests
: D.A.A.V. is a cofounder and stockholder for Novasenta, Tizona and Trishula; stockholder for Oncorus and Werewolf; has patents licensed and obtains royalties from Astellas, BMS and Novasenta; is a scientific advisory board member for Tizona, Werewolf, F-Star, Bicara, Apeximmune and T7/Imreg Bio; is a consultant for Astellas, BMS, Almirall, Incyte, G1 Therapeutics and Inzen Therapeutics; and receives research funding from BMS, Astellas and Novasenta. M.S.A. Is a consultant for Imcyse and Novartis and owns stock in Merck and Medtronic. A.V.J. is a co-inventor on a patent application concerning the described platform, has received research funding from Mitsubishi-Tanabe Pharma and has served as a consultant for Pfizer. The remaining authors declare no competing interests.